Two AI‑focused biotechs announced large financing rounds this week: Profluent raised $106 million to accelerate its AI protein‑design platform and commercial deployments across therapeutics, agriculture and biomanufacturing; Iambic closed $100 million to advance AI drug discovery models and cancer candidates. Both rounds attracted top-tier investors and signaled continued investor appetite for computational biology startups. Profluent touted a Protein Atlas with more than 115 billion proteins and collaborations with IDT and Revvity; Iambic highlighted its Enchant and NeuralPLexer models for clinical endpoint prediction and protein‑ligand structure forecasting. Both companies emphasized platform scalability and near‑term partnerships to translate AI output into bench‑validated leads and preclinical candidates. Clarification: AI protein design platforms use large datasets and generative models to propose novel protein sequences or structures that can be experimentally optimized into enzymes, antibodies or therapeutic proteins.